EUCTR2009-009977-85-FR进行中（未招募）1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2009-2010 Northern Hemisphere Season)
Sanofi Pasteur SA0 个研究点目标入组 131 人开始时间: 2009年4月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 131
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Aged 18 to 59 years (i.e. to the day before the 60th birthday) or 60 years or older (from the day of the 60th birthday) on the day of inclusion
- •2) Provision of a signed informed consent
- •3) Able to attend all scheduled visits and comply with all trial procedures
- •4) For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 3 weeks after vaccination
- •5) Entitled to national social security
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test at V01
- •2) Febrile illness (temperature =38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
- •3) Breast-feeding woman
- •4) Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination
- •5) Planned participation in another clinical trial during the present trial period
- •6) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- •7) Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and octoxynol-9, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing any of the same substances
- •8) Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- •9) Current alcohol abuse or drug addiction that may interfere with the subject’s ability to comply with trial procedures
- •10) Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
- •11) Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- •12) Planned receipt of any vaccine in the 3 weeks following the trial vaccination
- •13) Previous vaccination against influenza in the previous 6 months
- •14) Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion
- •15) Known Human Immunodeficiency Virus (HIV), HBs antigen or Hepatitis C seropositivity
- •16) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- •17) Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
研究者
相似试验
进行中（未招募）
1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) - Immunogenicity and Safety of a Vaccine against Influenza (2010-2011 NH season, intramuscular route)Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route.EUCTR2009-017690-38-FRSanofi Pasteur SA129
进行中（未招募）
不适用
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 NH season, intradermal route)EUCTR2009-017688-40-BESanofi Pasteur SA
已完成
不适用
Evaluation of immunogenicity of influenza vaccine in childreKCT0006127Korea University Ansan Hospital130
已完成
不适用
Immunogenicity and safety of conventional influenza vaccine in patients with type 2 diabetesCertain infectious and parasitic diseasesKCT0001423Transgovernmental Enterprise for Pandemic Influenza in Korea236
终止
不适用
sing influenza vaccination to understand and improve immune responses to vaccination in patients with chronic obstructive pulmonary disease (COPD) and healthy older people.Chronic Obstructive Pulmonary DiseaseInfluenza viral diseaseRespiratory - Chronic obstructive pulmonary diseaseInfection - Other infectious diseasesACTRN12620000830998Princess Alexandra Hospital171